1991 (landmark Italian trial): A double-blind, placebo-controlled trial involving 130 patients with Alzheimer's disease demonstrated that one year of ALCAR treatment resulted in a slower rate of deterioration compared to placebo across 13 of 14 outcome measures, including significant improvements in the Blessed Dementia Scale, logical intelligence, verbal critical abilities, long-term verbal memory, and selective attention [5][17]
The remaining authors declare no competing interests
Jaka Vukojevi, Marija Milavi, Darko Perovi, Spomenko Ili, Andrea Zemba ili, Nataa uran, Sanja trbe, Zoran Zorii, Igor Filipi, Petrana Brei, Sven Seiverth, & Predrag Sikiri
& Zheng, M
As discussed previously, fine-tuning TCR activation is critical for optimal activity of T cells, preventing anergy or exhaustion